EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies

Marta Torres-Ferrús iD, Victor J Gallardo iD, Alicia Alpuente iD, Edoardo Caronna iD, Eulalia Giné-Ciprés, Patricia Pozo-Rosich iD

Cephalalgia · 2024

DOI: 10.1177/03331024231222923 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cephalalgia, 2024. Verfasst von Marta Torres-Ferrús und 5 weiteren Autor:innen. Beteiligte Einrichtung: Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Hauptthemen laut MEDLINE: Depression, Migraine Disorders. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The present study aimed to describe the prevalence and evolution of depressive symptoms in a cohort of migraine patients treated with anti-CGRP monoclonal antibodies.

Methods

This is an exploratory, prospective, unicentric, one-year longitudinal study. We included migraine patients who started treatment with anti-CGRP monoclonal antibodies. Baseline demographic data, medical history, concomitant medication and migraine characteristics were collected. The presence of depressive symptoms was evaluated using the Beck Depression Inventory-II quarterly and treatment response was categorized according to the reduction in monthly headache days. A generalized mixed-effect regression model was used to model depression score over a one-year treatment taking into account frequency response rates.

Results

We included 577 patients: 84.2% females; median (range) age 47.0 (39.0–53.0) years, 46.1% (266/577) of them presented depressive symptoms at baseline (16.1% mild, 13.3% moderate and 16.6% severe). After six-month treatment, 47.4% (126/266) reduced headache frequency ≥50% after one year and 63.5% (169/266) achieved a clinically significant improvement in depression symptoms. We observed a 30.8% (−50.0%, −3.2%) main reduction in depression score during the first quarter. The improvement in depression symptoms was independently associated with headache frequency response: non-responders, −25.0% (−43.9%, −1.1%); partial responders, −30.2% (−51.3%, −7.6%); and good responders, −33.3% (−54.6%, −7.5%).

Conclusions

Anti-CGRP monoclonal antibodies targeting CGRP are effective in reducing depressive symptoms in patients with migraine. The main change of depression score happens during the first three months of treatment. The reduction in depressive symptoms is independent of migraine frequency improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DepressionMigraine DisordersFemaleHumansMiddle AgedMaleLongitudinal StudiesProspective StudiesCalcitonin Gene-Related PeptideHeadacheAntibodies, Monoclonal

Stichwörter der Autor:innen

CGRPCalcitonin gene-related peptidedepressionmigraine preventionmonoclonal antibodiestreatment

Substanzen

Calcitonin Gene-Related PeptideAntibodies, Monoclonal

Autor:innen und Institutionen

  • Headache Unit, Neurology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.

ORCID-Profile: Marta Torres-Ferrús, Victor J Gallardo, Alicia Alpuente, Edoardo Caronna, Patricia Pozo-Rosich

Zitieren

APA

Torres-Ferrús, M., Gallardo, V. J., Alpuente, A., Caronna, E., Giné-Ciprés, E., & Pozo-Rosich, P. (2024). Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies. Cephalalgia. https://doi.org/10.1177/03331024231222923

Vancouver

Torres-Ferrús M, Gallardo VJ, Alpuente A, Caronna E, Giné-Ciprés E, Pozo-Rosich P. Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies. Cephalalgia. 2024. doi:10.1177/03331024231222923

BibTeX
@article{TorresFerrs2024,
  author = {Torres-Ferrús, Marta and Gallardo, Victor J and Alpuente, Alicia and Caronna, Edoardo and Giné-Ciprés, Eulalia and Pozo-Rosich, Patricia},
  title = {Improvement of migraine depressive symptoms is not related to headache frequency: exploring the impact of anti-CGRP therapies},
  journal = {Cephalalgia},
  year = {2024},
  doi = {10.1177/03331024231222923}
}
Kostenlos starten →